In 1997, Bertin Technologies sets-up Ellipse Pharmaceuticals, its subsidiary on innovative Drug Fomulations.
Acquired in 2004, SPI-Bio (set-up in 1991) develops, manufactures & markets LST in long-term cooperation with the CEA. Aside from its products, SPI-Bio offers Services & Scientific expertise throughout non-preclinical & clinical stages.
Complementary to SPI-Bio business, Biotec Center specialised in Pharmacokinetics, Bioanalysis & Drug Metabolism studies is acquired in 2008, 20 years after its launch.
To broaden Ellipse business, IDPS (1999) is acquired to provide a complete range of Pharmaceutical Services for full development projects or stand-alone needs including highly potent drugs (development all conventional dosage forms, manufacturing and packaging for use in clinical trials).
In 2010, Bertin Pharma brings together its 4 subsidiaries: Biotec Centre, SPI-Bio, Ellipse Pharmaceuticals & IDPS.
In 2014, Bertin Pharma takes over the Johnson & Johnson Santé Beauté France (J&J SBF) site & team dedicated to Formulation & Production of Clinical Batches of OTC drugs.
In August 2017, Bertin Pharma refocuses its offer on Bioreagent and Bioanalytical tools providing and sales its Research Solutions activity to Oncodesign and Amatsi.